156 related articles for article (PubMed ID: 36964039)
1. Re: Germline Variants Associated with Toxicity to Immune Checkpoint Blockade.
Jones JO; Mitchell TJ; Stewart GD
Eur Urol; 2023 Dec; 84(6):597. PubMed ID: 36964039
[No Abstract] [Full Text] [Related]
2.
Meng XY
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37277194
[No Abstract] [Full Text] [Related]
3. Response to "
Aizenbud L; Schoenfeld DA; Caulfield JI; Mann JE; Austin MR; Perdigoto AL; Herold KC; Kluger HM
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349129
[No Abstract] [Full Text] [Related]
4. Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.
Caulfield JI; Aizenbud L; Perdigoto AL; Meffre E; Jilaveanu L; Michalek DA; Rich SS; Aizenbud Y; Adeniran A; Herold KC; Austin MR; Kluger H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898736
[TBL] [Abstract][Full Text] [Related]
5. Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma.
Montaudié H; Beranger GE; Reinier F; Nottet N; Martin H; Picard-Gauci A; Troin L; Ballotti R; Passeron T
Pigment Cell Melanoma Res; 2021 Sep; 34(5):978-983. PubMed ID: 33449414
[TBL] [Abstract][Full Text] [Related]
6. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Gupta T; Vinayak S; Telli M
Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
[TBL] [Abstract][Full Text] [Related]
7. Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.
Lu Z; Chen H; Jiao X; Wang Y; Wu L; Sun H; Li S; Gong J; Li J; Zou J; Yang K; Hu Y; Mao B; Zhang L; Zhang X; Peng Z; Lu M; Wang Z; Zhang H; Shen L
Genome Med; 2021 Nov; 13(1):175. PubMed ID: 34732240
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant immune checkpoint blockade revisited.
van Waalwijk van Doorn-Khosrovani SB; Huisman A; Roy AP; Koole S; Timmers L; Blank C; Gelderblom H
Lancet Oncol; 2023 Jul; 24(7):717-719. PubMed ID: 37414008
[No Abstract] [Full Text] [Related]
9. Immune-Checkpoint Blockade Therapy in Lymphoma.
Kuzume A; Chi S; Yamauchi N; Minami Y
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
[TBL] [Abstract][Full Text] [Related]
10. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.
Shukla SA; Bachireddy P; Schilling B; Galonska C; Zhan Q; Bango C; Langer R; Lee PC; Gusenleitner D; Keskin DB; Babadi M; Mohammad A; Gnirke A; Clement K; Cartun ZJ; Van Allen EM; Miao D; Huang Y; Snyder A; Merghoub T; Wolchok JD; Garraway LA; Meissner A; Weber JS; Hacohen N; Neuberg D; Potts PR; Murphy GF; Lian CG; Schadendorf D; Hodi FS; Wu CJ
Cell; 2018 Apr; 173(3):624-633.e8. PubMed ID: 29656892
[TBL] [Abstract][Full Text] [Related]
11. HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started.
Ivanova M; Shivarov V
Int J Immunogenet; 2021 Apr; 48(2):193-200. PubMed ID: 33112034
[TBL] [Abstract][Full Text] [Related]
12. Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma.
Isazadeh A; Hajazimian S; Garshasbi H; Shadman B; Baghbanzadeh A; Chavoshi R; Taefehshokr S; Farhoudi Sefidan Jadid M; Hajiasgharzadeh K; Baradaran B
J Cell Physiol; 2021 Feb; 236(2):791-805. PubMed ID: 32592235
[TBL] [Abstract][Full Text] [Related]
13. Multitumor Case Series of Germline
Kinget L; Bechter O; Punie K; Debruyne PR; Brems H; Clement P; Roussel E; Van Herck Y; Albersen M; Baldewijns M; Schöffski P; Beuselinck B
Curr Oncol; 2021 Aug; 28(5):3227-3239. PubMed ID: 34449592
[TBL] [Abstract][Full Text] [Related]
14. Review of immune checkpoint inhibitors in immuno-oncology.
Jacob JB; Jacob MK; Parajuli P
Adv Pharmacol; 2021; 91():111-139. PubMed ID: 34099106
[TBL] [Abstract][Full Text] [Related]
15. Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?
Chatzidionysiou K; Liapi M; Tsakonas G; Gunnarsson I; Catrina A
Clin Rheumatol; 2021 May; 40(5):1687-1695. PubMed ID: 32989505
[TBL] [Abstract][Full Text] [Related]
16. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
17. Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report.
Trabelsi Grati O; Zemoura L; Nhy C; Daniel C; Melaabi S; Callens C; Gauthier Villars M; Bièche I; Girard N
Lung Cancer; 2022 Dec; 174():186-187. PubMed ID: 36156246
[TBL] [Abstract][Full Text] [Related]
18. ["Immune checkpoint inhibitors in oncology"].
Daëron M; Vivier É
Rev Prat; 2021 Apr; 71(4):374-379. PubMed ID: 34161001
[TBL] [Abstract][Full Text] [Related]
19. Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variant MSH2 c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab.
Kiyomiya M; Fukuda K; Shimazu K; Yoshida T; Taguchi D; Shinozaki H; Nanjyo H; Shibata H
Jpn J Clin Oncol; 2023 Mar; 53(3):270-274. PubMed ID: 36484308
[TBL] [Abstract][Full Text] [Related]
20. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.
Willsmore ZN; Coumbe BGT; Crescioli S; Reci S; Gupta A; Harris RJ; Chenoweth A; Chauhan J; Bax HJ; McCraw A; Cheung A; Osborn G; Hoffmann RM; Nakamura M; Laddach R; Geh JLC; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Josephs DH; Papa S; Lacy KE; Karagiannis SN
Eur J Immunol; 2021 Mar; 51(3):544-556. PubMed ID: 33450785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
